Ebola outbreak prompts Feds to ante up more development funds for BioCryst antiviral

The National Institute of Allergy and Infectious Diseases (NIAID) exercises additional options to conduct Phase 1 clinical human safety trials and efficacy studies in non-human primates of BioCryst Pharmaceuticals' (BCRX +3.1%) broad-spectrum viral therapeutic, BCX4430, an RNA-dependent RNA polymerase inhibitor that has demonstrated activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

NIAID will pay BioCryst an additional $4.1M to develop BCX4430.

From other sites
Comments (2)
  • JeffCasey
    , contributor
    Comments (21) | Send Message
    "NIAID will pay BioCryst an additional $4.1M to develop BCX4430"
    Too late and too little.
    13 Aug 2014, 11:04 AM Reply Like
  • SivBum
    , contributor
    Comments (2741) | Send Message
    Gee, government intervention where are the capitalists to fund the R&D instead of taking public money? May be one of those countries with lower taxes should pony up.
    13 Aug 2014, 11:15 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs